Peanut food challenge, oral paste “placebo” - Placebo formulation, Viaskin Peanut, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut proteins, Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins
V712-305/EPOPEX
Phase 3 small_molecule active
Quick answer
Peanut food challenge, oral paste “placebo” - Placebo formulation, Viaskin Peanut, Peanut food challenge, oral paste “low dose” - 6.6 mg/g peanut proteins, Peanut food challenge, oral paste “high dose” - 133.3 mg/g peanut proteins for Peanut allergy is a Phase 3 program (small_molecule) at DBV Technologies with 1 ClinicalTrials.gov record(s).
Program details
- Company
- DBV Technologies
- Indication
- Peanut allergy
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active